Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism.
Acute-Phase Proteins
/ biosynthesis
Adult
Aged
Atherosclerosis
/ complications
Comorbidity
Datasets as Topic
Female
Follow-Up Studies
Gene Expression Regulation
Glial Cell Line-Derived Neurotrophic Factor
/ biosynthesis
Humans
Interferon-gamma
/ biosynthesis
Interleukin-15 Receptor alpha Subunit
/ biosynthesis
Machine Learning
Male
Middle Aged
N-Acetylgalactosaminyltransferases
/ biosynthesis
Oxidative Stress
Prospective Studies
Protein Interaction Maps
Protein-Arginine Deiminase Type 2
/ biosynthesis
Proteome
Pulmonary Embolism
/ genetics
Pulmonary Surfactants
Quantitative Trait Loci
Transcriptome
Venous Thromboembolism
/ metabolism
Polypeptide N-acetylgalactosaminyltransferase
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
13 05 2021
13 05 2021
Historique:
received:
17
12
2019
accepted:
18
12
2020
pubmed:
3
2
2021
medline:
15
12
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism Project, a multicenter prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE patients (n = 96) against those of patients with DVT-associated PE (n = 276) or isolated DVT (n = 160). This resulted in the identification of shared molecular processes between PE phenotypes, as well as an isolated PE-specific protein signature. Shared processes included upregulation of inflammation, response to oxidative stress, and the loss of pulmonary surfactant. The isolated PE-specific signature consisted of 5 proteins: interferon-γ, glial cell line-derived neurotrophic growth factor, polypeptide N-acetylgalactosaminyltransferase 3, peptidyl arginine deiminase type-2, and interleukin-15 receptor subunit α. These proteins were orthogonally validated using cis protein quantitative trait loci. External replication in an independent population-based cohort (n = 5778) further validated the proteomic results and showed that they were prognostic for incident primary isolated PE in individuals without history of VTE (median time to event: 2.9 years; interquartile range: 1.6-4.2 years), supporting their possible involvement in the early pathogenesis. This study has identified molecular overlaps and differences between VTE phenotypes. In particular, the results implicate noncanonical pathways more commonly associated with respiratory and atherosclerotic disease in the acute pathophysiology of isolated PE.
Identifiants
pubmed: 33529319
pii: S0006-4971(21)00236-6
doi: 10.1182/blood.2019004571
pmc: PMC9635523
doi:
Substances chimiques
Acute-Phase Proteins
0
GDNF protein, human
0
Glial Cell Line-Derived Neurotrophic Factor
0
Interleukin-15 Receptor alpha Subunit
0
Proteome
0
Pulmonary Surfactants
0
Interferon-gamma
82115-62-6
N-Acetylgalactosaminyltransferases
EC 2.4.1.-
PADI2 protein, human
EC 3.5.3.15
Protein-Arginine Deiminase Type 2
EC 3.5.3.15
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2681-2693Informations de copyright
© 2021 by The American Society of Hematology.
Références
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Thromb Res. 2019 Sep;181:84-91
pubmed: 31374513
Clin Imaging. 2008 Sep-Oct;32(5):335-41
pubmed: 18760719
Cardiovasc Res. 2004 Mar 1;61(4):671-82
pubmed: 14985064
Front Immunol. 2018 Nov 20;9:2696
pubmed: 30515171
Blood Coagul Fibrinolysis. 2015 Dec;26(8):903-7
pubmed: 26218971
J Virol. 2015 Dec 04;90(4):1788-801
pubmed: 26637460
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2872-2877
pubmed: 30100058
Chest. 2000 Nov;118(5):1405-11
pubmed: 11083693
Immunology. 1999 Feb;96(2):207-14
pubmed: 10233697
Eur J Pharmacol. 2017 Dec 5;816:93-106
pubmed: 28893577
Circulation. 2011 Sep 27;124(13):1435-41
pubmed: 21900083
J Cell Commun Signal. 2018 Dec;12(4):745-751
pubmed: 30191398
J Cancer. 2018 Aug 6;9(17):3046-3057
pubmed: 30210627
Eur Respir J. 2014 Mar;43(3):801-7
pubmed: 23988762
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
Am J Physiol Lung Cell Mol Physiol. 2011 May;300(5):L790-8
pubmed: 21335521
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Chest. 2009 Mar;135(3):786-793
pubmed: 18812453
Open Forum Infect Dis. 2016 Dec 20;3(4):ofw214
pubmed: 28018924
Chest. 1995 Jan;107(1 Suppl):10S-17S
pubmed: 7813322
Thromb Res. 2014 Aug;134(2):259-63
pubmed: 24909892
Microcirculation. 2001 Apr;8(2):71-88
pubmed: 11379793
Arthritis Res Ther. 2015 Jan 20;17:9
pubmed: 25600626
Haematologica. 2013 Feb;98(2):309-15
pubmed: 22801962
Chest. 2020 Jul;158(1):341-349
pubmed: 32217063
Circ Res. 2014 Mar 14;114(6):947-56
pubmed: 24425713
Eur J Intern Med. 2009 Sep;20(5):470-3
pubmed: 19712846
Proc Am Thorac Soc. 2005;2(4):355-60; discussion 371-2
pubmed: 16267362
Front Immunol. 2012 Nov 29;3:360
pubmed: 23264775
Cytokine Growth Factor Rev. 2015 Dec;26(6):673-85
pubmed: 26005197
Oncotarget. 2016 Aug 2;7(31):49008-49026
pubmed: 27356750
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Immunity. 2009 Oct 16;31(4):539-50
pubmed: 19833085
Elife. 2015 Jul 13;4:e07847
pubmed: 26167653
Respir Res. 2017 Dec 29;18(1):218
pubmed: 29287593
Matrix Biol. 2018 Aug;68-69:67-80
pubmed: 29572156
Nucleic Acids Res. 2002 Apr 1;30(7):1575-84
pubmed: 11917018
AJR Am J Roentgenol. 2009 Dec;193(6):1488-93
pubmed: 19933638
J Cell Sci. 2003 Oct 1;116(Pt 19):3855-62
pubmed: 12953054
Int J Lab Hematol. 2013 Jun;35(3):254-61
pubmed: 23590652
Ann Thorac Cardiovasc Surg. 2015;21(5):409-17
pubmed: 26354232
Allergy. 2009 Jan;64(1):104-11
pubmed: 19076536
J Immunol. 2008 Oct 1;181(7):5089-97
pubmed: 18802113
Blood. 2016 Aug 11;128(6):753-62
pubmed: 27354721
Lancet. 2000 Jul 15;356(9225):182-3
pubmed: 10963193
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Jun;55(6-7):824-9
pubmed: 22736163
Cytokine Growth Factor Rev. 2006 Jun;17(3):157-71
pubmed: 16481210
Eur J Prev Cardiol. 2021 Aug 9;28(9):1009-1018
pubmed: 34402876